The Houston metro area's population grew by more than 90,000 people between 2017 and 2018, according to the U.S. Census Bureau. Photo by Zview/Getty Images

The meteoric rise of the Houston metro area's population continues skyward. From 2017 to 2018, the region added about 251 residents per day, according to population estimates released by the U.S. Census Bureau.

Put another way, the Houston-The Woodlands-Sugar Land region gained 91,689 residents in just one year, the Census Bureau says. That's as if the region absorbed a city around the size of, well, Sugar Land, every 365 days.

All in all, the Houston area ranked third in numeric population growth from 2017 to 2018 among U.S. metro areas with at least 1 million residents, the bureau's estimates show. On July 1, 2017, the bureau counted an estimated 6,905,695 residents in the Houston area. On the same date on July 1, 2018, the area's population stood at 6,997,384. The bureau's estimates take into account people moving into and out of the Houston area, as well as births and deaths.

If you think that growth rate is impressive, consider the Houston area's leap in population from 2010 to 2018.

For that period, Houston ranked second among all U.S. metro areas for population growth on a numeric basis. The Census Bureau says the region's headcount shot up about 18.2 percent from 2010 to 2018, going from 5,920,487 to 6,997,384.

Fort Bend has done its part to feed the Houston area's growth. Among U.S. counties, Fort Bend County ranked 10th for population growth on a percentage basis from 2017 to 2018. The headcount spiked 34.7 percent, from 584,690 to 787,858.

Elsewhere in Texas:

  • Dallas-Fort Worth led U.S. metro areas for numeric growth in population from 2017 to 2018, adding 131,767 residents. In just one year, the region's population rocketed from 7,407,944 to 7,539,711 (1.8 percent).
  • The Austin metro area's population grew 2.5 percent from 2017 to 2018, going from 2,115,230 to 2,168,316, an added 53,086 residents.
  • The population of the San Antonio metro area grew 1.8 percent from 2017 to 2018, going from 2,474,274 to 2,518,036. In that one-year span, the area added 43,762 residents.
  • For 2017 to 2018, Comal County ranked sixth among U.S. counties for percentage growth in population. The number of residents jumped 36.8 percent, from 108,485 to 148,373.
  • In seventh place for percentage population growth among U.S. counties from 2017 to 2018 was Kendall County. The number of residents soared 36.6 percent, from 33,411 to 45,641.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.